NYSE, EBS - Emergent Biosolutions
We are a profitable multinational biopharmaceutical company focused on the
development, manufacture and commercialization of immunobiotics, consisting of
vaccines and therapeutics that assist the body?s immune system to prevent or
treat disease. We manufacture and market BioThrax ?, also referred to as anthrax
vaccine adsorbed, or AVA, the only vaccine approved by the U.S. Food and Drug
Administration, or FDA, for the prevention of anthrax infection. We use
internally generated cash flows from the sale of BioThrax to fund the
development of a product pipeline that addresses a variety of infectious
diseases and other medical conditions.
We develop immunobiotics for use against infectious diseases that have resulted
in significant unmet or underserved public health needs and against biological
agents that are potential weapons of bioterrorism and biowarfare. ...
Read SEC Filing on NASDAQ.com »